Verastem Oncology announced the launch of the new healthcare professional component of Let?s Talk About LGSOC, designed to support clinicians in the diagnosis and management of low-grade serous ovarian cancer (LGSOC). Let?s Talk About LGSOC provides detailed information about the unique clinical, histopathological, and molecular features of LGSOC, current National Comprehensive Cancer Network® (NCCN®) clinical practice guidelines and additional medical and scientific information and resources. LGSOC of the ovary, fallopian tubes, and peritoneum is a rare tumor that commonly affects younger women, with a median age of diagnosis between 45-55 years.

For many patients, LGSOC symptoms and treatment side effects have a long-lasting impact on physical and mental health. To date, limited treatment options are available for LGSOC and no treatments have yet been approved by regulatory authorities specifically for the treatment of LGSOC with doctors and patients often resorting to using treatments that may have originally been developed for other tumors. LGSOC represents approximately 10% of all ovarian cancers with an estimated 1,000 to 2,000 patients diagnosed each year with more than 6,000 patients living with its impact in the United States and 80,000 worldwide.

LGSOC is primarily driven by the RAS/MAPK pathway, a key contributor to tumor development and progression. The majority of patients with LGSOC are diagnosed with advanced stage disease that has spread beyond its primary site. It is relatively resistant to chemotherapy and highly recurrent.

More than 80% of people with LGSOC will have their cancer come back after remission.